August 2010- Volume 6, Issue 8

August 2010

In this Issue

Omics & Systems Biology

Pushing the limits of phosphoproteomics

Pushing the limits of phosphoproteomics

Purdue University researcher patents new retrieval method that makes studying cancer proteins easier

Ariadne’s thread of connections

Ariadne’s thread of connections

Bioinformatics company to collaborate in multimillion-dollar EU-based neuromuscular disease consortium to find biomarkers

Boosting R&D with a little M&A

Boosting R&D with a little M&A

Gilead Sciences acquires CGI Pharmaceuticals and adds numerous small- molecule kinase inhibitor compounds to its pipeline

A class of their own

A class of their own

Santaris Pharma, miRagen Therapeutics to develop microRNAs for treatment of cardiovascular disease

Multimillion miRNA deal

Multimillion miRNA deal

sanofi-aventis, Regulus form strategic alliance in microRNA therapeutics

Special Reports

Let’s work together

Let’s work together

Peeling back the layers of integrated approaches to oncology research

The big picture

The big picture

Multiple approaches—and ultimately, more comprehensive ones—are critical to understanding and treating cancer

New Products

Automates preparation of fragment libraries

Automates preparation of fragment libraries

Beckman Coulter Genomics has introduced the SPRIworks Fragment Library System II.

Research & Development

Getting under their skin

Getting under their skin

Valeant and Biovail agree to merge, creating leader in dermatology and neurology pharmaceuticals

sanofi-aventis continues R&D spending spree

sanofi-aventis continues R&D spending spree

French pharma acquires U.S. biopharmaceutical firm TargeGen for $75 million

Lilly acquisition blossoms

Lilly acquisition blossoms

Company to pay as much as $380 million for Alnara

Fail-safe product and deal

Fail-safe product and deal

Option agreement between Cadence Pharmaceuticals and Incline Therapeutics gives Cadence two option periods to acquire Incline

Celgene reaches into deep pockets again

Celgene reaches into deep pockets again

Enticed by tumor drug, Celgene acquires Abraxis BioScience for nearly $3 billion upfront and up to $650 million if certain goals are met

Diagnostics

TRANSCENDing a typical partnership

TRANSCENDing a typical partnership

MIT’s Koch Institute collaborates with Ortho-McNeil-Janssen and affiliates in oncology R&D

A personal touch for cancer therapy

A personal touch for cancer therapy

Aeterna Zentaris to collaborate with Almac on therapy and companion diagnostic in multiple oncology targets

Signed on the dotted line

Signed on the dotted line

Signature Diagnostics to use Affymetrix microarray technology for detecting and predicting progression of colorectal cancer

Rheumatoid arthritis reprise

Rheumatoid arthritis reprise

TcLand Expression, a spinoff of Inserm Transfert, rejoins former partner to pursue RA companion diagnostics

Global News

A pain-free alliance

A pain-free alliance

Servier and Galapagos initiate strategic alliance in osteoarthritis

That’s Italian

That’s Italian

Aptuit to acquire operations at GSK’s Medicines Research Centre in Verona

The potential of Polish science

The potential of Polish science

Selvita and Orion collaborate on Alzheimer’s disease program

From the Buckeye State to Beijing

From the Buckeye State to Beijing

BioOhio, Beijing Pharma forge international biomedical, business partnership

Instruments & Informatics

Sosei to acquire Activus Pharma

Sosei to acquire Activus Pharma

Deal marks Sosei’s continued efforts to grow through non-organic means

Picking up the slack … and then some

Picking up the slack … and then some

Eurofins MWG Operon and Genomatix join forces to offer advanced NGS

Getting a signal

Getting a signal

Promega, SignalChem to offer complete kinase solutions

Human genomics for the masses

Human genomics for the masses

Roche and IBM collaborate on nanopore-based DNA sequencing technology with eyes toward advancing personalized healthcare

Commentary

Where will innovation come from?

Where will innovation come from?

In the early 1980s, I traveled to Berlin and to China for the first time. To reach Berlin, you flew in a PanAm DC-9 from Frankfurt, your only choice of airline and departure airport. It was a beautiful day. Crossing the border to East Germany, many things disappeared: color, highways, modern buildings and traffic. From low altitudes, it appeared that 30 to 40 years had just been lost.

Editor's Focus

ddn dissects current cancer craze

ddn dissects current cancer craze

Business deals and agreements associated with cancer research are plentiful these days, and this month, ddn’s editors and writers give you several examples of the latest oncology-related acquisitions, mergers and partnerships to be signed in this burgeoning area of pharmaceutical and biological research.

Contract Services

Back to the future with Parkinson’s research

Back to the future with Parkinson’s research

Michael J. Fox Foundation partners with leading CROs to develop biomarker candidates for Parkinson’s disease

Changing the channel

Changing the channel

Milestone-driver collaboration between Essen BioScience and Nycomed boosts ion-channel drug discovery

A gem of a partnership

A gem of a partnership

Emerald BioStructures, FORMA Therapeutics partner to develop treatments for lymphoma and other cancers

Going for prime time

Going for prime time

Quintiles inks deal with University Malaya Medical Center in Malaysia
Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

March 2023 Magazine Front Cover

Latest Issue  

• Volume 19 • Issue 3 • March 2023

March 2023

March 2023 Issue